25B-NBOMe
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 1026511-90-9  |
| ATC code | ? |
| PubChem | CID 9977044 |
| ChemSpider | 8152636 |
| Chemical data | |
| Formula | C18H22BrNO3 |
| Mol. mass | 380.275 g/mol |
|
|
|
|
 (what is this?) (verify) |
|
25B-NBOMe (NBOMe-2C-B, BOM 2-CB, Cimbi-36, New Nexus) is a derivative of the phenethylamine hallucinogen 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5HT2A receptor.[1][2][3] Anecdotal reports from human users[citation needed] suggest 25B-NBOMe to be an active hallucinogen at a dose of as little as 400-650mcg insufflated,[citation needed] making it a similar potency to other phenethylamine derived hallucinogens such as bromo-dragonfly. Duration of effects lasts about 10h.[citation needed]
The carbon-11 labelled version of this compound ([11C]Cimbi-36) was synthesized and validated as a radiotracer for positron emission tomography (PET) in Copenhagen.[4][5][6] As a 5-HT2A receptor agonist PET radioligand, [11C]Cimbi-36 was hypothesized to provide a more functional marker of these receptors. Also, [11C]Cimbi-36 is investigated as a potential marker of serotonin release and thus could serve as an indicator of serotonin levels in vivo. Distubances in both 5-HT2A receptor signalling and serotonin levels are involved in the pathophysiology of human diseases such as depression and schizophrenia.
[edit] See also
- 2CBCB-NBOMe (NBOMe-TCB-2)
- 2CBFly-NBOMe (NBOMe-2CB-Fly)
- 2C-C-NBOMe (NBOMe-2CC)
- 25I-NBOMe (NBOMe-2CI)
- 2C-TFM-NBOMe (NBOMe-2C-TFM)
- 25I-NBMD (NBMD-2CI)
- 25I-NBOH (NBOH-2CI)
- 25I-NBF (NBF-2CI)
- 5-MeO-NBpBrT
[edit] References
- ^ Ralf Heim PhD. Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts. (German)
- ^ Maria Silva PhD. Theoretical study of the interaction of agonists with the 5-HT2A receptor. Universität Regensburg, 2009.
- ^ Silva ME, Heim R, Strasser A, Elz S, Dove S (January 2011). "Theoretical studies on the interaction of partial agonists with the 5-HT(2A) receptor". Journal of Computer-aided Molecular Design 25 (1): 51–66. doi:10.1007/s10822-010-9400-2. PMID 21088982.
- ^ Hansen, M. Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain. PhD Thesis, University of Copenhagen, 2011.
- ^ Ettrup, A. E. A. ; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M. et al. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–693. doi:10.1007/s00259-010-1686-8. ISBN 0025901016868. PMID 21174090.
- ^ Ettrup, A.; Holm, S. R.; Hansen, M.; Wasim, M.; Santini, M. A.; Palner, M.; Madsen, J.; Svarer, C. et al. (2013). "Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand \11C]Cimbi-36". Molecular Imaging and Biology. doi:10.1007/s11307-012-0609-4.
 |
This psychedelics, dissociatives and deliriants-related article is a stub. You can help Wikipedia by expanding it. |
